Ranbaxy Settles MDL Antitrust Claims For $485M
Ranbaxy Pharmaceuticals Inc. will pay $485 million to settle a multidistrict suit claiming it manipulated the Food and Drug Administration's generic-drug approval process to stop competitors from developing generic versions of...To view the full article, register now.
Already a subscriber? Click here to view full article